symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ASLN,1.29,1.667473,28357,21507525,0,1.12-4.69,0.02,ASLAN Pharmaceuticals Limited,USD,0001722926,US04522R1014,04522R101,NASDAQ Global Market,NASDAQ,Biotechnology,https://aslanpharma.com,"ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.","Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.",Healthcare,SG,34,65 6222 4235,83 Clemenceau Avenue,Singapore,,239920,,1.37259,https://financialmodelingprep.com/image-stock/ASLN.png,2018-05-04,False,False,True,True,False
